NewVale Capital is a sector-specialist pharma services growth equity firm investing in proven, revenue-generating services and enabling technology businesses serving the life sciences ecosystem. We partner with management teams to provide right-sized capital and focused support to enhance commercial execution, strengthen core infrastructure, and build durable, scalable platforms.
We invest exclusively in the services architecture that underpins the life sciences ecosystem – leveraging deep customer knowledge and connectivity to drive operational improvement and sustainable commercial growth.
Lab and research services and enabling technologies that support early stage drug discovery.
Services and enabling technologies that support clinical research and clinical trial execution.
Services and enabling technologies that support pharmaceutical manufacturing, quality, and supply chain operations.
Services and enabling technologies that support launch execution, adoption, and ongoing performance of commercial therapeutics.
Our perspective is shaped by direct experience building, operating and investing across the life sciences continuum, from early discovery to commercialization of therapeutics. We bring that lens to every investment, applying a deep understanding of customer priorities to refine go-to-market strategy, strengthen operational foundations, and build platforms designed to scale.
Operating Partner
Operating Partner
Operating Partner
Managing Partner
Executive Partner
Executive Partner
Principal
Principal
Vice President
Associate
Vice President,
Finance and Operations
November 10, 2025
Rick Hancock Appointed as CEO to Lead Next Phase of Growth – Argonaut Manufacturing Services
September 10, 2025
NewVale Capital Leads $30 Million Growth Investment in Noxilizer
May 13, 2024
NewVale Capital Debuts With Oversubscribed $167 Million Fund to Invest in the Services Architecture of the Life Science Industry
March 5, 2024
Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners
